Five Prime Therapeutics
Five Prime Therapeutics Newswire

Five Prime Therapeutics Newswire

Comprehensive Real-Time News Feed for Five Prime Therapeutics.

Results 1 - 20 of 74 in Five Prime Therapeutics

  1. Prenatal DNA test patent invalid, U.S. appeals court saysRead the original story

    Friday Jun 12 | Reuters

    A U.S. appeals court said on Friday that the discovery of a new form of prenatal testing that avoids the risks of invasive medical techniques was good for science but did not deserve a patent. The U.S. Court of Appeals for the Federal Circuit in the District of Columbia said a patent held by genetic testing company Sequenom Inc on detecting fetal DNA in a pregnant woman's blood was invalid.

    Comment?

  2. Prenatal DNA Test Patent Invalid, U.S. Appeals Court SaysRead the original story

    Tuesday Jun 9 | Medical Daily

    A U.S. appeals court said on Friday that the discovery of a new form of prenatal testing that avoids the risks of invasive medical techniques was good for science but did not deserve a patent. The U.S. Court of Appeals for the Federal Circuit in the District of Columbia said a patent held by genetic testing company Sequenom Inc on detecting fetal DNA in a pregnant woman's blood was invalid.

    Comment?

  3. UPDATE 1-Prenatal DNA test patent invalid, U.S. appeals court saysRead the original story

    Friday Jun 12 | Reuters

    A U.S. appeals court said on Friday that the discovery of a new form of prenatal testing that avoids the risks of invasive medical techniques was good for science but did not deserve a patent. The U.S. Court of Appeals for the Federal Circuit in the District of Columbia said a patent held by genetic testing company Sequenom Inc on detecting fetal DNA in a pregnant woman's blood was invalid.

    Comment?

  4. Roche holds hope for second test of Alzheimer's drugRead the original story w/Photo

    Tuesday Jun 9 | Star Tribune

    Roche Holding is weighing a second test for an experimental Alzheimer's drug that failed in an initial study, after a similar offering from Biogen showed promise. Roche stopped a trial of gantenerumab in December because patients weren't benefiting more than those receiving a placebo.

    Comment?

  5. Roche takes another shot at Alzheimer's drugRead the original story w/Photo

    Tuesday Jun 9 | Salt Lake Tribune

    Geneva a Roche Holding is weighing a second test for an experimental Alzheimer's drug that failed in an initial study, after a similar offering from Biogen showed promise in slowing the memory-robbing ailment. Roche stopped a trial of gantenerumab in December because patients weren't benefiting more than those receiving a placebo.

    Comment?

  6. Global Agricultural Enzymes Market 2015 to 2019 report published by Market Research StoreRead the original story

    Tuesday Jun 2 | Emailwire.com

    Market Research Store has uploaded latest Report on "Global Agricultural Enzymes Market 2015-2019' Strategic Analysis and Industry Outlook between 2015 to 2019. Deerfield Beach, Florida About Agricultural Enzymes Agricultural enzymes are complex protein molecules derived from sources such as plant tissue, animal tissue, and microbes.

    Comment?

  7. Global Agricultural Enzymes Market Grows at 7% CAGR to 2019 Worldwide Forecasts a New Research ReportRead the original story

    May 30, 2015 | Emailwire.com

    The analysts forecast global agricultural enzymes market to grow at a CAGR of 7.26 percent over the period 2014-2019. Agricultural enzymes are complex protein molecules derived from sources such as plant tissue, animal tissue, and microbes.

    Comment?

  8. Investment Analysts' Recent Ratings Changes for Five Prime TherapeuticsRead the original story

    May 29, 2015 | AmericanBankingNews.com

    Several brokerages have updated their recommendations and price targets on shares of Five Prime Therapeutics in the last few weeks: 5/28/2015 - Five Prime Therapeutics was given a new $31.00 price target on by analysts at BMO Capital Markets. They now have a "buy" rating on the stock.

    Comment?

  9. Five Prime To Present At The Jefferies and Co. Healthcare ConferenceRead the original story

    May 28, 2015 | BioSpace

    Five Prime Therapeutics, Inc. , a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today announced that Lewis T. "Rusty" Williams, M.D., Ph.D., President and Chief Executive Officer, will present at the Jefferies Healthcare Conference in New York City on Thursday, June 4 at 8:30 AM Eastern Daylight Time. The live webcast will be accessible at or directly at http://wsw.com/webcast/jeff88/fprx .

    Comment?

  10. Five Prime Therapeutics Given a $31.00 Price Target by BMO Capital Markets AnalystsRead the original story

    May 28, 2015 | AmericanBankingNews.com

    ... Analysts at Oppenheimer reiterated an "outperform" rating and set a $45.00 price target on shares of Five Prime Therapeutics in a research note on Wednesday. Analysts at Zacks upgraded shares of Five Prime Therapeutics from a "sell" rating to a ...

    Comment?

  11. Five Prime Therapeutics Earns Outperform Rating from OppenheimerRead the original story

    May 27, 2015 | AmericanBankingNews.com

    ... number of other analysts have also recently weighed in on FPRX. Analysts at Zacks upgraded shares of Five Prime Therapeutics from a "sell" rating to a "hold" rating in a research note on Tuesday, May 19th. Analysts at Guggenheim initiated coverage ...

    Comment?

  12. Wednesday's Pre-Market Insights: PBR, SDRL, WDAY, EMC, BLUERead the original story

    May 27, 2015 | GuruFocus.com

    ... of Piper Jaffray after the biopharmaceutical company announced an exclusive license agreement with Five Prime Therapeutics to collaborate on cancer therapies. TipRanks uses machine learning and language processing algorithms to measure the ...

    Comment?

  13. bluebird bio Climbs on $131.5 Million Car T Pact With Five Prime Therapeutics, Inc.Read the original story

    May 26, 2015 | BioSpace

    bluebird bio, Inc. (Nasdaq:BLUE) and Five Prime Therapeutics, Inc. (Nasdaq:FPRX) today announced that they have entered into an exclusive license agreement to research, develop and commercialize chimeric antigen receptor (CAR) T cell therapies using ...

    Comment?

  14. bluebird bio and Five Prime Therapeutics Enter into License Agreement ...Read the original story w/Photo

    May 26, 2015 | GlobeNewswire

    bluebird bio, Inc. (Nasdaq: BLUE ) and Five Prime Therapeutics, Inc. (Nasdaq: FPRX ) today announced that they have entered into an exclusive license agreement to research, develop and commercialize chimeric antigen receptor (CAR) T cell therapies ...

    Comment?

  15. Five Prime Therapeutics, Inc. Announces First Quarter 2015 Financial ResultsRead the original story

    May 13, 2015 | BioSpace

    Five Prime Therapeutics, Inc. , a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today provided a corporate update and reported financial results for the first quarter ending March 31, 2015. "We made important progress in all of our programs during the first quarter of 2015 and remain on track to deliver on a number of key milestones over the next 12 months," said Lewis T. "Rusty" Williams, M.D., Ph.D., Founder and Chief Executive Officer of Five Prime.

    Comment?

  16. Five Prime Therapeutics' (FPRX) CEO Lewis Williams on Q1 2015 Results - Earnings Call TranscriptRead the original story w/Photo

    May 13, 2015 | Seeking Alpha

    Good day, ladies and gentlemen, and welcome to the Five Prime Therapeutics 2015 Q1 quarterly earnings call. [Operator Instructions] I would now like to introduce your host for today's conference, Aron Knickerbocker, Chief Business Officer for Five Prime.

    Comment?

  17. Five Prime Therapeutics, Inc. To Announce First Quarter 2015...Read the original story

    May 7, 2015 | BioSpace

    Five Prime Therapeutics, Inc. , a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, will report its first quarter financial results on Wednesday, May 13, 2015, after the U.S. financial markets close. Five Prime will host a conference call and live audio webcast on Wednesday, May 13, 2015 at 5:00 p.m. /2:00 p.m. to discuss the company's financial results and provide a general business update.

    Comment?

  18. Roche nominates Smith & Nephew CFO to boardRead the original story w/Photo

    May 8, 2015 | MarketWatch

    Roche Holding AG said Friday it was nominating the chief financial officer of medical equipment maker Smith & Nephew PLC to its board of directors after long-serving member Dame DeAnne Julius chose not to run for re-election. Basel-based Roche said its board had nominated Julie Brown to replace Dame Julius, who has served since 2002.

    Comment?

  19. Five Prime Therapeutics, Inc. To Present At The Antibody DayRead the original story

    May 3, 2015 | BioSpace

    Five Prime Therapeutics, Inc. , a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today announced that Aron Knickerbocker, Chief Business Officer, and Brian Wong, Vice President, Research and Head of Immuno-Oncology, will present at the Credit Suisse Antibody Day on Wednesday, May 6 at 3:00 PM Eastern Daylight Time. The conference will take place at Credit Suisse's offices at One Madison Avenue, New York City.

    Comment?

  20. Five Prime Therapeutics to Present at the Credit Suisse Antibody DayRead the original story w/Photo

    May 1, 2015 | GlobeNewswire

    Five Prime Therapeutics, Inc. , a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today announced that Aron Knickerbocker, Chief Business Officer, and Brian Wong, Vice President, Research and Head of Immuno-Oncology, will present at the Credit Suisse Antibody Day on Wednesday, May 6 at 3:00 PM Eastern Daylight Time. The conference will take place at Credit Suisse's offices at One Madison Avenue, New York City.

    Comment?